Effects of empagliflozin in women and men with acute myocardial infarction - an analysis from the EMMY trial
Source : https://www.sciencedirect.com/science/article/pii/S1109966623001008?via=ihub
Empagliflozin exerts beneficial cardiac effects in people with acute myocardial infarction. Women with acute myocardial infarction are older and have higher NTproBNP levels than men.
Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.
Share
Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction - Experimental & Molecular Medicine
Source : https://www.nature.com/articles/s12276-023-01002-3
Two existing drugs used to lower glucose in patients with diabetes also reduce the chances of heart failure by blocking the excessive activity of a protein involved in transport of...
Conclusions/Relevance: These findings suggest that both EMPA and SOTA exert cardioprotective effects in the DM-HFrEF zebrafish model by inhibiting NHE1 activity. In addition, despite the similar cardioprotective effects of the two drugs, SOTA may be less effective than EMPA at high concentrations.
Share
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Source : https://www.sciencedirect.com/science/article/abs/pii/S2213177923001865?via=ihub
In the CANVAS (Canagliflozin Cardiovascular Assessment Study) program, canagliflozin reduced the risk of heart failure (HF) hospitalization among individuals with type 2 diabetes mellitus (T2DM).
Conclusions: Among participants with T2DM, the WATCH-DM and TRS-HFDM can reliably identify those at high risk for HF hospitalization and most likely to benefit from canagliflozin.
Share
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37240080/
The purpose of this manuscript is to review the effects of sodium-glucose cotransport protein 2 inhibitors (SGLT2is) in patients with chronic kidney disease according to basic mechanisms, current recommendations, and...
Conclusions/Relevance: A large unmet need remains to reduce the residual risk in patients with cardiovascular or renal disease. The results from ongoing and future randomized, controlled trials will certainly expand the clinical indications for SGLT-2is in a large range of patients, enabling us to discover and unlock their value beyond the...
Share
Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)
Heart failure (HF) is a complex clinical disease characterized by symptoms and indications caused by any anatomical or functional impairment of ventricular filling or blood ejection. As one of the...
Relevance: The purpose of the trial is to validate the changes that occur in gut microbiota in patients with HFpEF who take empagliflozin and to investigate the function of gut microbiota and their metabolites in the process.
Share